Why Exelixis Jumped 10% in September

Shares of Exelixis (NASDAQ: EXEL) rose 10% in September, according to data from S&P Global Market Intelligence, after the company announced a series of positive developments throughout the month related to various cancer therapies.

Exelixis is already on track to generate $1 billion in annual sales in 2021 through its primary drug Cabometyx, which is approved to treat first- and second-line renal cell carcinoma as well as advanced hepatocellular carcinoma.

Image source: Getty Images.

Continue reading

Source Fool.com